Contactless point-of-care detection of latent tuberculosis biomarker Hsp16.3 using a high-sensitivity magnetoimpedance biosensor
6
Issued Date
2026-04-01
Resource Type
ISSN
09244247
Scopus ID
2-s2.0-105034361405
Journal Title
Sensors and Actuators A Physical
Volume
400
Rights Holder(s)
SCOPUS
Bibliographic Citation
Sensors and Actuators A Physical Vol.400 (2026)
Suggested Citation
Pornprom T., Pakamwong B., Sangswan J., Punkvang A., Thongdee P., Suttisintong K., Leanpolchareanchai J., Hongmanee P., Lumjiaktase P., Chailapakul O., Jampasa S., Pungpo P., Thiabgoh O. Contactless point-of-care detection of latent tuberculosis biomarker Hsp16.3 using a high-sensitivity magnetoimpedance biosensor. Sensors and Actuators A Physical Vol.400 (2026). doi:10.1016/j.sna.2026.117493 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/116069
Title
Contactless point-of-care detection of latent tuberculosis biomarker Hsp16.3 using a high-sensitivity magnetoimpedance biosensor
Corresponding Author(s)
Other Contributor(s)
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains a leading cause of infectious disease-related mortality worldwide, with latent tuberculosis infection (LTBI) presenting a major diagnostic challenge. Heat shock protein 16.3 (Hsp16.3), a latency-associated antigen strongly expressed during dormancy, has emerged as a promising biomarker for LTBI detection. However, conventional diagnostic methods are costly, complex, and infrastructure-dependent, underscoring the need for portable and reagent-free biosensing solutions. Here, we report a contactless biosensing platform based on the giant magnetoimpedance (GMI) effect for the detection of Hsp16.3. The system integrates a commercial pico-Tesla resolution amorphous wire sensor with an Arduino-based microcontroller and MCP3223 analog-to-digital converter. Detection relies on binding-induced magnetic field perturbations generated by antibody- functionalized iron-oxide nanoparticles, and antibody-antigen complexes, which modulate the local magnetic fields and induce measurable impedance changes. The biosensor achieved reproducible detection of Hsp16.3 in model assays, with limits of detection of ∼99 µg/mL for antibody titration and ∼44 µg/mL for antigen response. More importantly, the platform was successfully validated with plasma samples from LTBI patients, demonstrating specific responses to antibody-antigen complexes in complex biological matrices. This work represents the first demonstration of a GMI-biosensor validated with LTBI plasma samples, highlighting its potential as a portable, scalable, and reagent-free diagnostic tool for future development toward early TB screening in resource-limited settings.